Gamifant Purple Book BLA 761107
- BLA number
- 761107
- Proprietary names
- Gamifant
- Proper names
- emapalumab-lzsg
- Applicant
- Swedish Orphan Biovitrum AB (publ)
- Center
- CDER
- First observed release
- 2020-05-01
- Latest observed release
- 2026-06-01
- Newest archive release
- 2026-06-01
- FDA patent list
- No patents listed in the captured FDA patent list; source updated 2025-06-11
- Coverage
- Present in newest release
Latest Known Product Presentations#
Product, Proprietary name, Proper name table| Product | Proprietary name | Proper name | License type | Strength | Dosage form | Route | Presentation | Marketing | Licensure | Approval | Patent list provided |
|---|
| 001 | Gamifant | emapalumab-lzsg | 351(a) | 10MG/2ML (5MG/ML) | Injection | Intravenous | Single-Dose Vial | Rx | Licensed | 2018-11-20 | |
| 002 | Gamifant | emapalumab-lzsg | 351(a) | 50MG/10ML (5MG/ML) | Injection | Intravenous | Single-Dose Vial | Rx | Licensed | 2018-11-20 | |
| 003 | Gamifant | emapalumab-lzsg | 351(a) | 100MG/20ML (5MG/ML) | Injection | Intravenous | Single-Dose Vial | Rx | Licensed | 2020-06-26 | |
| 004 | Gamifant | emapalumab-lzsg | 351(a) | 50MG/2ML (25MG/ML) | Injection | Intravenous | Single-Dose Vial | Rx | Licensed | 2023-06-07 | |
| 005 | Gamifant | emapalumab-lzsg | 351(a) | 100MG/4ML (25MG/ML) | Injection | Intravenous | Single-Dose Vial | Rx | Licensed | 2023-06-07 | |
| 006 | Gamifant | emapalumab-lzsg | 351(a) | 250MG/10ML (25MG/ML) | Injection | Intravenous | Single-Dose Vial | Rx | Licensed | 2023-06-07 | |
Published Patent List#
No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.
Official Monthly Change Events#
Release, Event, Product table| Release | Event | Product | Name | License type | Status | Applicant |
|---|
| 2025-07-01 | N | 004 | Gamifant | 351(a) | Rx | Swedish Orphan Biovitrum AB (publ) |
| 2025-07-01 | N | 005 | Gamifant | 351(a) | Rx | Swedish Orphan Biovitrum AB (publ) |
| 2025-07-01 | N | 006 | Gamifant | 351(a) | Rx | Swedish Orphan Biovitrum AB (publ) |
| 2020-08-01 | U | 001 | Gamifant | 351(a) | Rx | Swedish Orphan Biovitrum AB (publ) |
| 2020-08-01 | U | 002 | Gamifant | 351(a) | Rx | Swedish Orphan Biovitrum AB (publ) |
| 2020-08-01 | N | 003 | Gamifant | 351(a) | Rx | Swedish Orphan Biovitrum AB (publ) |
| 2020-05-01 | R | 001 | Gamifant | 351(a) | Rx | Novimmune SA |
| 2020-05-01 | R | 002 | Gamifant | 351(a) | Rx | Novimmune SA |
Observed Product State History#
Release, Product, Name table| Release | Product | Name | License type | Marketing | Licensure | Approval |
|---|
| 2025-07-01 | 004 | Gamifant | 351(a) | Rx | Licensed | 2023-06-07 |
| 2025-07-01 | 005 | Gamifant | 351(a) | Rx | Licensed | 2023-06-07 |
| 2025-07-01 | 006 | Gamifant | 351(a) | Rx | Licensed | 2023-06-07 |
| 2020-08-01 | 003 | Gamifant | 351(a) | Rx | Licensed | 2020-06-26 |
| 2020-05-01 | 001 | Gamifant | 351(a) | Rx | Licensed | 2018-11-20 |
| 2020-05-01 | 002 | Gamifant | 351(a) | Rx | Licensed | 2018-11-20 |